We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

African-Specific Molecular Taxonomy of Prostate Cancer Revealed

By LabMedica International staff writers
Posted on 06 Sep 2022
Print article
Image: Histopathology of mucinous fibroplasia in prostate cancer (Photo courtesy of Cleveland Clinic)
Image: Histopathology of mucinous fibroplasia in prostate cancer (Photo courtesy of Cleveland Clinic)

Prostate cancer is characterized by considerable geo-ethnic disparity. African ancestry is a significant risk factor for the disease, with 2.7-fold higher mortality rates across sub-Saharan Africa than global averages, yet the genetic and non-genetic factors underlying this is not known.

Prostate cancer is characterized by a highly variable natural history and diverse clinical behaviors; it is not surprising that genome profiling has revealed extensive intra- and intratumor heterogeneity and complexity. The identification of oncogenic subtypes and actionable drug targets are moving prostate cancer management a step closer to the promise of precision medicine.

A large team of international scientists led by those at the University of Sydney, Camperdown, Australia) included in a study 183 treatment-naive patients with prostate cancer who were recruited from Australia (n = 53), Brazil (n = 7) and South Africa (n = 123). While matched for pathological grading, prostate-specific antigen levels are notably elevated within the African patients. DNA extracted from fresh tissue and matched blood underwent 2 × 150 bp sequencing on the NovaSeq instrument (Illumina, San Diego, CA, USA). The team performed whole-genome sequencing (WGS) to generate a large cancer genomics resource for sub-Saharan Africa that includes around two million somatic variants.

The scientists reported that findings specific to patients of African ancestry include an elevated tumor mutational burden, increased percentage of genome alteration, a greater number of predicted damaging mutations and a higher total of mutational signatures, and various cancer driver genes. They also describe a molecular taxonomy for prostate cancer differentiated by ancestry and defined as global mutational subtypes, while uncovering different evolutionary trajectories and mutational processes that suggest both common genetic and environmental factors contribute to the disparity between ethnicities. Significant African-ancestry-specific findings included an elevated tumor mutational burden, increased percentage of genome alteration, a greater number of predicted damaging mutations and a higher total of mutational signatures, and the driver genes NCOA2, STK19, DDX11L1, PCAT1 and SETBP1.

The authors concluded that their study suggests that larger genomic datasets of geo-ethnically diverse and ancestrally defined populations in a unified analysis will continue to identify rare and geographically restricted subtypes in prostate cancer and potentially other cancers. They demonstrated that ancestral and geographical attributes of patients could facilitate studies on cancer population genomics, an alternative to cancer personalized genomics, for a better scientific understanding of nature versus nurture. The study was published on August 31, 2022 in the journal Nature.

Related Links:
University of Sydney
Illumina 

New
Gold Supplier
Real-Time PCR System
STC-96A Plus
New
STI Test Kit
PlexPCR HSV-1&2, VZV
New
1,5-AG Test
1,5-Anhydroglucitol Test Kit
New
Zika Virus IgM µ-Capture ELISA
https://www.ibl-international.com/en/zika-virus-igm-capture-elisa

Print article
IIR Middle East

Channels

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.